Table 3.
Hazard ratios (HR) for Overall survival (OS) and Progression-free survival (PFS). PFS and OS and corresponding 95%CI and p-values. Multivariate model
| OS | PFS | ||||
|---|---|---|---|---|---|
| Clinicopathologic characteristics | HR (95%CI) | p | HR (95%CI) | p | |
| BMI – kg/m2 | continuous | 0.96 (0.91–1.01) | 0,15 | – | – |
| ECOG – OMS | 1 vs 0 | 2.34 (1.49–3.67) | <0.001 | 1.71 (1.18–2.47) | <0,01 |
| Treatment line | 2 vs 1 | – | – | 1.67 (0.97–2.84) | 0,06 |
| Co-medication | Corticosteroids | 1.20 (0.77–1.89) | 0,41 | – | – |
| ACE inhibitors | 1.96 (1.09–3.51) | 0,02 | 1.89 (1.14–3.16) | 0,01 | |
| ATB | 0.84 (0.47–1.49) | 0,55 | 0.73 (0.44–1.20) | 0,21 | |
Hazard ratios (HR) and 95% confidence interval (CI) were estimated from a multivariate Cox Proportion Hazard model.
Wald test was used to test if each HR was statistically significantly different from 1.
ACE: angiotensin-converting-enzyme. ARA2: angiotensin II receptor antagonists. ATB: antibiotics. BMI: body mass index. ADK: adenocarcinoma. EPI: squamous cell. LA: locally advanced. META: metastatic